Alzheimer's Disease Trial, Recruiting NCT07618481 Sponsor: Ruijin Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07618481
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Alzheimer's disease based on recognised medical guidelines
  • You are between 50 and 80 years old
  • You have had a specific brain scan (called an Aβ-PET scan) that came back positive for Alzheimer's-related changes
  • You have a regular caregiver who can help you take part in daily activities as part of the study
  • Any ongoing health conditions you have have been stable for at least 30 days
  • You have enough vision and hearing to complete tests — at minimum, you can detect light and hold a basic conversation
  • You are able to walk on your own or with the help of a walking aid
  • You are willing and able to give your signed agreement to take part voluntarily

Who may not be able to join:

  • You have a history of epilepsy or seizures
  • You are unable to have an MRI scan, or your MRI scan showed significant abnormalities
  • You scored above 6 on a standard depression screening tool used for older adults (confirm with trial site)
  • You are currently having thoughts of suicide, or have attempted suicide in the past 6 months
  • You have another major brain or nervous system condition, such as Parkinson's disease, Lewy body dementia, frontotemporal dementia, Huntington's disease, multiple sclerosis, or a history of serious brain infections or multiple concussions, among others (confirm with trial site for the full list)
  • You have a psychiatric disorder
  • You have severe heart disease, or serious ongoing liver, kidney, or breathing conditions, or poorly controlled diabetes or thyroid disease
  • You have had problems with drug or alcohol misuse in the past 12 months
  • You are currently receiving a type of Alzheimer's treatment called an anti-amyloid antibody therapy (confirm with trial site)
  • You have taken a medication called memantine within the 30 days before the study begins
  • Your life expectancy is estimated to be less than 24 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
31 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Montreal Cognitive Assessment - Basic (MoCA-B) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov